Claims for Patent: 9,752,193

Summary for Patent: 9,752,193

Title:	Gene and mutations thereof associated with seizure and movement disorders
Abstract:	The present invention relates to the proline rich transmembrane protein 2 (PRRT2) gene, and the identification of mutations and variations in PRRT2 that give rise to seizure and movement disorders. Accordingly, the present invention provides methods for the diagnosis or prognosis of such disorders by identifying alterations in the PRRT2 gene. Identification of alterations in the PRRT2 gene also enables the identification of subjects with an increased likelihood of having an offspring predisposed to such disorders. The present invention also provides an isolated nucleic acid molecule comprising an alteration in the PRRT2 gene, wherein said alteration produces a seizure and/or movement disorder phenotype. Also provided is an isolated PRRT2 polypeptide that comprises an alteration which produces a seizure and/or movement disorder phenotype. Furthermore, the present invention provides kit for diagnosing or prognosing a seizure and/or movement disorder in a subject, or for identifying a subject with an increased likelihood of having an offspring predisposed to a seizure and/or movement disorder, wherein the kit includes one or more components for testing for the presence of an alteration in the PRRT2 gene in the subject.
Inventor(s):	Heron; Sarah Elizabeth (Highbury, AU), Dibbens; Leanne Michelle (College Park, AU), Berkovic; Samuel Frank (Melbourne, AU), Scheffer; Ingrid Eileen (Melbourne, AU), Mulley; John Charles (Firle, AU)
Assignee:	The University of Melbourne (Victoria, AU) Central Adelaide Local Health Network Incorporated (Adelaide, AU) Itek Ventures Pty Ltd (University of South Australia) (Salisbury South, AU)
Application Number:	14/354,461
Patent Claims:	1. A method for detecting a variant PRRT2 gene in a biological sample from a human subject, the method comprising: a) contacting a variant PRRT2 gene in a biological sample from a human subject with a detectably labeled oligonucleotide that specifically hybridizes to an alteration in a variant proline rich transmembrane protein 2 (PRRT2) nucleic acid but does not bind to a wild-type PRRT2 nucleic acid not comprising the alteration; and b) detecting hybridization of the oligonucleotide to the variant PRRT2 nucleic acid; wherein detecting hybridization indicates the presence of a variant PRRT2 gene in the sample; wherein said alteration in a variant PRRT2 nucleic acid is selected from the group consisting of: c.629-630insC, c.649-650insC, IVS2+1 G>T, IVS2+5G>A, and c.950G>A. 2. The method according to claim 1, wherein the alteration in the PRRT2 nucleic acid is c.629-630insC or c.649-650insC, which are both frameshift mutations in exon 2 of the PRRT2 gene. 3. The method according to claim 2, wherein the alteration is c.649-650insC, which is the result of an insertion of a cytosine (C) nucleotide residue after the nucleotide residue at a position corresponding to position 649 of SEQ ID NO: 9. 4. The method according to claim 1, wherein the alteration in the PRRT2 nucleic acid is IVS2+1 G>T or IVS2+5G>A, which are both splice site mutations in intron 2 of the PRRT2 gene. 5. The method according to claim 4, wherein the alteration is IVS2+1 G>T, which is the result of a guanine (G) to thymine (T) nucleotide substitution at a position corresponding to position +1 of intron 2 of the PRRT2 gene. 6. The method according to claim 1, wherein the alteration is c.950G>A, which is the result of a guanine (G) to adenine (A) nucleotide substitution at a position corresponding to position 950 of SEQ ID NO: 9. 7. The method according to claim 1, wherein the detectably labeled oligonucleotide is labelled with a fluorescent moiety. 8. The method according to claim 1, wherein the detectably labeled oligonucleotide is at least 20 nucleotides in length. 9. The method according to claim 4, wherein the alteration is IVS2+5G>A, which is the result of a guanine (G) to adenine (A) nucleotide substitution at a position corresponding to position +5 of intron 2 of the PRRT2 gene.

Details for Patent 9,752,193

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2031-10-28
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2031-10-28
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2031-10-28